Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Latest from Memorial Sloan Kettering Cancer Center

The Future of Frontline CLL Treatment Hinges on Chemotherapy-Free Approaches

May 03, 2022

Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.

Checkpoint Blockade Before Allogeneic Transplant Improves PFS, But Not OS, in Hodgkin Lymphoma

April 07, 2022

Checkpoint inhibitors prior to allogeneic hematopoietic cell transplant improved progression-free survival and relapse incidence in patients with Hodgkin lymphoma, but the treatment did not improve non-relapse mortality or overall survival.

Breast Cancer Management Grows With Innovative, Better Tailored Treatment

March 13, 2022

The historical boundaries of what was possible in the management of patients with breast cancer continue to be challenged, evidenced by the use of HER2-directed therapies in patients with brain metastases, de-escalated approaches in patients with visceral disease, and less-invasive surgical techniques for patients with lymph node involvement.

Biomarkers of Response Steer Treatment Selection in Breast Cancer

March 11, 2022

Tiffany Traina, MD, discusses the body of evidence supporting the use of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, shifting standards of care in HER2-positive disease, as well as biomarkers of response with checkpoint inhibitors and PARP inhibitors in triple-negative breast cancer.

Copanlisib Plus Ibrutinib Produces High Response Rate in Relapsed/Refractory MCL, But Limited by Additive Toxicity

March 08, 2022

Although the addition of copanlisib to ibrutinib resulted in a high overall response rate in patients with relapsed/refractory mantle cell lymphoma, the regimen was found to have additive toxicity, according to findings from a small phase 1 trial.

Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML

February 28, 2022

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.